Archer-Daniels-Midland Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Archer-Daniels-Midland Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.27B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $85.53B | Feb 17, 2026 |
| FY2023 | Dec 31, 2023 | $22.98B | Nov 18, 2024 |
| FY2023 | Sep 30, 2023 | $21.70B | Nov 18, 2024 |
| FY2023 | Jun 30, 2023 | $25.19B | Nov 18, 2024 |
| FY2023 | Mar 31, 2023 | $24.07B | Nov 18, 2024 |
| FY2023 | Dec 31, 2022 | $25.94B | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $24.68B | Nov 18, 2024 |
| FY2023 | Jun 30, 2022 | $27.28B | Nov 18, 2024 |
| FY2023 | Mar 31, 2022 | $23.65B | Nov 18, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.96B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $24.37B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $25.69B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $27.61B | Feb 20, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.03B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.78B | Feb 17, 2026 |
| FY2023 | Dec 31, 2023 | $1.74B | Nov 18, 2024 |
| FY2023 | Sep 30, 2023 | $1.81B | Nov 18, 2024 |
| FY2023 | Jun 30, 2023 | $1.88B | Nov 18, 2024 |
| FY2023 | Mar 31, 2023 | $2.08B | Nov 18, 2024 |
| FY2023 | Dec 31, 2022 | $1.76B | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $1.81B | Nov 18, 2024 |
| FY2023 | Jun 30, 2022 | $2.10B | Nov 18, 2024 |
| FY2023 | Mar 31, 2022 | $1.90B | Nov 18, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.80B | Feb 17, 2026 |
| FY2023 | Dec 31, 2023 | $565.00M | Nov 18, 2024 |
| FY2023 | Sep 30, 2023 | $821.00M | Nov 18, 2024 |
| FY2023 | Jun 30, 2023 | $927.00M | Nov 18, 2024 |
| FY2023 | Mar 31, 2023 | $1.17B | Nov 18, 2024 |
| FY2023 | Dec 31, 2022 | $1.02B | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $1.03B | Nov 18, 2024 |
| FY2023 | Jun 30, 2022 | $1.24B | Nov 18, 2024 |
| FY2023 | Mar 31, 2022 | $1.05B | Nov 18, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $269.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $256.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $216.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $171.00M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $160.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $154.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $141.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $129.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $123.00M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.61B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.71B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $3.46B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.36B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.99B | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $2.69B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $2.49B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $2.17B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $1.98B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.98B | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.45B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.79B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.46B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.48B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $6.60B | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | ($2.39B) | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | ($5.45B) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($4.78B) | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | ($5.97B) | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | ($6.51B) | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.56B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.49B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.32B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.17B | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $823.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $828.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $842.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $1.05B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $882.00M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.39B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $53.27B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $54.63B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $59.77B | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | $56.14B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $49.72B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $44.00B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $40.83B | Feb 18, 2020 |
| FY2018 | Jan 1, 2018 | $39.96B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $39.96B | Feb 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.77B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.51B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.10B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $4.16B | Feb 20, 2025 |
| FY2022 | Dec 31, 2021 | $4.18B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.45B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $3.39B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $2.50B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $2.37B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $2.25B | Feb 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.98B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $21.93B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $23.47B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $23.65B | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | $21.66B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $19.78B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $18.96B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $18.53B | Feb 18, 2020 |
| FY2018 | Jan 1, 2018 | $17.55B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $17.55B | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $611.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.37B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.04B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $943.00M | Nov 18, 2024 |
| FY2022 | Dec 31, 2020 | $666.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $852.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $2.00B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $804.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $619.00M | Feb 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.61B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $8.25B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $8.26B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $8.68B | Nov 18, 2024 |
| FY2022 | Dec 31, 2021 | $8.58B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $7.89B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $7.68B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $8.28B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $6.64B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $6.78B | Feb 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 17, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Nov 18, 2024 |
| FY2023 | Sep 30, 2023 | 1 | Nov 18, 2024 |
| FY2023 | Jun 30, 2023 | 1 | Nov 18, 2024 |
| FY2023 | Mar 31, 2023 | 2 | Nov 18, 2024 |
| FY2023 | Dec 31, 2022 | 1 | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | 1 | Nov 18, 2024 |
| FY2023 | Jun 30, 2022 | 2 | Nov 18, 2024 |
| FY2023 | Mar 31, 2022 | 1 | Nov 18, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 17, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Nov 18, 2024 |
| FY2023 | Sep 30, 2023 | 1 | Nov 18, 2024 |
| FY2023 | Jun 30, 2023 | 1 | Nov 18, 2024 |
| FY2023 | Mar 31, 2023 | 2 | Nov 18, 2024 |
| FY2023 | Dec 31, 2022 | 1 | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | 1 | Nov 18, 2024 |
| FY2023 | Jun 30, 2022 | 2 | Nov 18, 2024 |
| FY2023 | Mar 31, 2022 | 1 | Nov 18, 2024 |